The global hemoglobinopathy treatment market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The growth of the market is primarily attributed to a surge in the cases of hemoglobinopathies, as well as the public awareness of hemoglobin disorders. According to the World Health Organization, about 1.1% of the expecting parents globally are at the risk of having a child with hemoglobin disorder. Adding to this, a strong product pipeline aiming towards the treatment of hemoglobinopathies coupled with the constant endeavours from the market players and government in developing the new therapies for the treatment of hemoglobinopathies are projected to uplift the market.
A full report of Hemoglobinopathy Treatment Market is available at: https://www.omrglobal.com/industry-reports/hemoglobinopathy-treatment-market
Likewise, various government and private organizations led initiatives such as neonatal screening to detect the potential disorders are further projected to fuel the market growth. Along with the governmental programs, rising approvals for novel therapies from the regulatory bodies are expected to boost the market growth. For instance, in 2019, the FDA approved Reblozyl, Adakveo, Zynteglo, and Oxbryta for the treatment of haemoglobin disorders.
Some key players operating in the market include Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc., Celgene Corp. These players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in May 2017, Sangamo Therapeutics and Pfizer announced a collaboration for haemophilia A gene therapy. Such collaborations are further anticipated to drive market growth. Further, in December 2017, CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated entered into a partnership to develop and commercialize novel gene-editing treatments for thalassemia using CRISPR/Cas9 technology.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hemoglobinopathy-treatment-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
- Competitive Landscape: Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc., Celgene Corp, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Hemoglobinopathy Treatment Market by Segment
By Treatment
• Stem Cell Therapy
• Blood Transfusion
• Iron Chelation Therapy
• Others
By Application
• Thalassemia
• Sickle Cell Anaemia
• Others
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
